Isoform-Specific HDAC Inhibitors for Selective Enzyme Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack selective and isoform-specific histone deacetylase (HDAC) inhibitors, which are crucial for targeting specific HDAC family members and treating associated diseases with greater potency and reduced side effects.
Innovation Solution
Development of novel cinnamic hydroxymate compounds that selectively inhibit Class IIa HDACs (HDAC4, 5, 7, and 9) and other HDAC isoforms, providing both non-selective and selective HDAC inhibitors for various therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective HDAC inhibitors are used, then HDAC activity is inhibited, but side effects increase due to lack of specificity
Solution Approach 1:
The HDAC family is segmented into multiple isoforms (HDAC1-HDAC11) that can be targeted individually. The patent develops selective inhibitors for specific HDAC classes (I, II, III, IV) and isoforms (e.g., HDAC9, HDAC7), allowing precise targeting of specific enzymes rather than inhibiting all HDACs non-selectively. This segmentation enables treatment of specific diseases associated with particular HDAC isoforms while avoiding off-target effects.
Solution Approach 2:
Different HDAC inhibitors are designed with specific local chemical properties to target specific HDAC isoforms. The patent employs class-specific and isoform-specific inhibitors with distinct molecular structures that bind preferentially to particular HDAC members. For example, certain inhibitors are optimized for Class IIa HDACs (HDAC4, 5, 7, 9) while others target Class I HDACs, creating local quality differentiation in the inhibitor population to achieve selective biological effects.
2Reliability
If selective HDAC inhibitors are developed, then side effects are reduced, but compound complexity increases
Solution Approach 1:
The patent identifies universal binding motifs and pharmacophores that can be applied across multiple HDAC inhibitors. Certain structural frameworks (e.g., hydroxamic acid, peptide-based inhibitors) serve as universal templates that can be modified to target different HDAC classes and isoforms. This multi-functionality approach allows a single design principle to generate multiple selective inhibitors, reducing overall complexity compared to developing entirely new compounds for each target.
Solution Approach 2:
Selective HDAC inhibitors are generated by systematically changing molecular parameters such as substituent groups, steric configurations, and binding site interactions. The patent employs structure-activity relationship (SAR) analysis to modify specific parameters of lead compounds to achieve selectivity for particular HDAC isoforms. By optimizing parameters like molecular weight, functional group positioning, and chiral configuration, the patent achieves specificity without requiring fundamentally complex compound architectures.
3Productivity
If isoform-specific inhibitors are used, then treatment efficacy is improved, but manufacturing complexity increases
Solution Approach 1:
The patent employs high-throughput screening and computational chemistry methods to pre-identify and pre-optimize candidate inhibitors for specific HDAC isoforms before clinical development. Virtual screening of large chemical libraries allows preliminary selection of promising compounds with predicted high affinity and selectivity for target isoforms. This preliminary action filters out unsuitable candidates early, reducing the complexity of subsequent manufacturing and formulation processes by focusing resources only on the most promising inhibitors.
Solution Approach 2:
The patent utilizes structure-based drug design where three-dimensional structural information of HDAC isoforms is copied and used to design inhibitors with complementary binding geometries. Molecular modeling and docking simulations create virtual copies of the HDAC binding sites that guide the synthesis of selective inhibitors. This copying approach allows rational design of isoform-specific inhibitors based on conserved structural motifs, simplifying the manufacturing process by leveraging known structural relationships across HDAC family members.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively inhibit HDAC activity, offering potential treatments for proliferative diseases, autoimmune diseases, neurodegenerative disorders, vascular diseases, and other conditions associated with HDAC activity, with improved specificity and reduced side effects.
Implementation Method 1
These compounds effectively inhibit HDAC activity
Data Source
AI summary
HDAC inhibitors of the general formula (I) and (II) and pharmaceutically acceptable salts thereof, as described herein, are useful as inhibitors of histone deacetylases or other deacetylases, and thus are useful for the treatment of various diseases and disorders associated with acetylase/deacetylase activity as described herein (e.g., cancer). In certain embodiments, the compounds of the invention selectively target either a class or isoform of the HDAC family. Another aspect of the invention provides an assay for determining the inhibitory effect of a test compound on an HDAC protein comprising: incubating the HDAC protein with a substrate of general formula (IIIc) in the presence of a test compound; and determining the activity of the HDAC protein.